Results 1 - 20 of 545 for All Library Resources
Sorted by:
Sorted by:
RelevanceOr hit Enter to replace sort method
- Relevance
- Date-newest
- Date-oldest
- Popularity
- Author
- Title
Show only
- Peer-reviewed Journals (520)
| Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
|---|---|---|---|
| 1 |
Material Type: Article
|
|
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaThe New England journal of medicine, 2020-05, Vol.382 (20), p.1894-1905 [Peer Reviewed Journal]Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1915745 ;PMID: 32402160Full text available |
| 2 |
Material Type: Article
|
|
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian CancerThe New England journal of medicine, 2019-12, Vol.381 (25), p.2416-2428 [Peer Reviewed Journal]Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1911361 ;PMID: 31851799Full text available |
| 3 |
Material Type: Article
|
|
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancerAnnals of oncology, 2021-09, Vol.32 (9), p.1137-1147 [Peer Reviewed Journal]2021 The Authors ;Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1016/j.annonc.2021.06.004 ;PMID: 34139272Full text available |
| 4 |
Material Type: Article
|
|
FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular CarcinomaClinical cancer research, 2021-04, Vol.27 (7), p.1836-1841 [Peer Reviewed Journal]2020 American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.CCR-20-3407 ;PMID: 33139264Full text available |
| 5 |
Material Type: Article
|
|
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)The Lancet (British edition), 2017-10, Vol.390 (10103), p.1654-1663 [Peer Reviewed Journal]2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Oct 7, 2017 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(17)31607-0 ;PMID: 28756902Full text available |
| 6 |
Material Type: Article
|
|
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trialThe Lancet (British edition), 2016-04, Vol.387 (10026), p.1405-1414 [Peer Reviewed Journal]Elsevier Ltd ;2016 Elsevier Ltd ;Copyright © 2016 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Apr 2, 2016 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(15)01238-6 ;PMID: 26719230 ;CODEN: LANCAOFull text available |
| 7 |
Material Type: Article
|
|
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group StudyJournal of clinical oncology, 2019-06, Vol.37 (16), p.1380-1390 [Peer Reviewed Journal]2019 by American Society of Clinical Oncology 2019 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.18.01568 ;PMID: 31002578Full text available |
| 8 |
Material Type: Article
|
|
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialThe lancet oncology, 2019-05, Vol.20 (5), p.625-635 [Peer Reviewed Journal]2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;2019. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(19)30035-X ;PMID: 30975627Full text available |
| 9 |
Material Type: Article
|
|
Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical TrialJournal of clinical oncology, 2021-04, Vol.39 (10), p.1098-1107 [Peer Reviewed Journal]2021 by American Society of Clinical Oncology 2021 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.20.02447 ;PMID: 33560877Full text available |
| 10 |
Material Type: Article
|
|
Lomustine and Bevacizumab in Progressive GlioblastomaThe New England journal of medicine, 2017-11, Vol.377 (20), p.1954-1963 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1707358 ;PMID: 29141164Full text available |
| 11 |
Material Type: Article
|
|
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent GlioblastomaClinical cancer research, 2021-02, Vol.27 (4), p.1048-1057 [Peer Reviewed Journal]2020 American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.CCR-20-2500 ;PMID: 33199490Full text available |
| 12 |
Material Type: Article
|
|
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trialAnnals of oncology, 2022-02, Vol.33 (2), p.181-192 [Peer Reviewed Journal]2021 European Society for Medical Oncology ;Copyright © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1016/j.annonc.2021.11.010 ;PMID: 34839016Full text available |
| 13 |
Material Type: Article
|
|
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trialThe lancet oncology, 2017-06, Vol.18 (6), p.779-791 [Peer Reviewed Journal]Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jun 1, 2017 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(17)30279-6 ;PMID: 28438473Full text available |
| 14 |
Material Type: Article
|
|
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyThe lancet oncology, 2015-10, Vol.16 (13), p.1306-1315 [Peer Reviewed Journal]Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Oct 2015 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(15)00122-9 ;PMID: 26338525 ;CODEN: LANCAOFull text available |
| 15 |
Material Type: Article
|
|
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 studyCancer cell, 2021-09, Vol.39 (9), p.1279-1291.e3 [Peer Reviewed Journal]2021 Elsevier Inc. ;Copyright © 2021 Elsevier Inc. All rights reserved. ;ISSN: 1535-6108 ;EISSN: 1878-3686 ;DOI: 10.1016/j.ccell.2021.07.005 ;PMID: 34388377Full text available |
| 16 |
Material Type: Article
|
|
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trialThe lancet oncology, 2016-11, Vol.17 (11), p.1543-1557 [Peer Reviewed Journal]Elsevier Ltd ;2016 Elsevier Ltd ;Copyright © 2016 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Nov 01, 2016 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(16)30172-3 ;PMID: 27660192 ;CODEN: LANCAOFull text available |
| 17 |
Material Type: Article
|
|
Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of PrematurityPediatrics (Evanston), 2016-04, Vol.137 (4), p.1-1 [Peer Reviewed Journal]Copyright © 2016 by the American Academy of Pediatrics. ;Copyright American Academy of Pediatrics Apr 2016 ;ISSN: 0031-4005 ;EISSN: 1098-4275 ;DOI: 10.1542/peds.2015-3218 ;PMID: 27244705 ;CODEN: PEDIAUFull text available |
| 18 |
Material Type: Article
|
|
Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility StudyClinical cancer research, 2017-06, Vol.23 (11), p.2730-2741 [Peer Reviewed Journal]2016 American Association for Cancer Research. ;Copyright American Association for Cancer Research Inc Jun 1, 2017 ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.CCR-16-0437 ;PMID: 28119364Full text available |
| 19 |
Material Type: Article
|
|
The role of bevacizumab in the treatment of glioblastomaJournal of neuro-oncology, 2017-07, Vol.133 (3), p.455-467 [Peer Reviewed Journal]Springer Science+Business Media New York 2017 ;Journal of Neuro-Oncology is a copyright of Springer, 2017. ;ISSN: 0167-594X ;EISSN: 1573-7373 ;DOI: 10.1007/s11060-017-2477-x ;PMID: 28527008Full text available |
| 20 |
Material Type: Article
|
|
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)Annals of oncology, 2016-08, Vol.27 (8), p.1539-1546 [Peer Reviewed Journal]2016 European Society for Medical Oncology ;The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdw206 ;PMID: 27177863Full text available |
Results 1 - 20 of 545 for All Library Resources
Sorted by:
Sorted by:
RelevanceOr hit Enter to replace sort method
- Relevance
- Date-newest
- Date-oldest
- Popularity
- Author
- Title
Personalize your results
Refine Search Results
Expand My Results
Show only
- Peer-reviewed Journals (520)
Refine My Results
Creation Date
- Before 2015 (7)
- 2015 To 2016 (163)
- 2017 To 2018 (109)
- 2019 To 2021 (143)
- After 2021 (124)
-
More options
New Records
Resource Type
- Articles (544)
- Book Chapters (1)
-
More options
Subject
- Bevacizumab - Adverse Effects (544)
- Humans (543)
- Science & Technology (497)
- Life Sciences & Biomedicine (478)
- Bevacizumab (361)
- Female (356)
- Oncology (290)
- Middle Aged (289)
- Male (282)
- Aged (273)
- Bevacizumab - Administration & Dosage (253)
- Adult (212)
- Antineoplastic Combined Chemotherapy Protocols - Adverse Effects (191)
- Angiogenesis Inhibitors - Adverse Effects (178)
- Chemotherapy (161)
- Bevacizumab - Therapeutic Use (158)
- Monoclonal Antibodies (146)
- Treatment Outcome (139)
- Patients (132)
- Immunotherapy (128)
-
More options
Databases
- MEDLINE (544)
- ProQuest Central (297)
- GFMER Free Medical Journals (247)
- Open Access: PubMed Central (234)
- DOAJ Directory of Open Access Journals (197)
- ROAD: Directory of Open Access Scholarly Resources (160)
- HighWire Press (Free Journals) (85)
- SpringerOpen (67)
- Open Access: Wiley-Blackwell Open Access Journals (49)
- Journals@Ovid Open Access Journal Collection Rolling (25)
- IngentaConnect Backfiles (25)
- Nature Free (24)
- Freely Accessible Japanese Titles - check A-Z of ejournals (24)
- Open Access: Freely Accessible Journals by multiple vendors (16)
- Wolters Kluwer Open Access (15)
- Open Access: Oxford University Press Open Journals (15)
- ProQuest One Psychology (13)
- BMJ Open Access Journals (12)
- KoreaMed (Open access) (12)
- Medknow Medical Journals (Open access) (10)
-
More options
Language
- English (536)
- Japanese (56)
- French (4)
- Chinese (3)
- Spanish (3)
- Portuguese (2)
- Czech (1)
-
More options
Journal Title
- Annals Of Oncology (22)
- Anticancer Research (18)
- Bmc Cancer (14)
- Cancer Chemotherapy And Pharmacology (20)
- Cancer Medicine (18)
- Clinical Cancer Research (21)
- Journal Of Clinical Oncology (13)
- Journal Of Neuro-Oncology (14)
- Medicine (15)
- The Oncologist (13)
-
More options
|
||||
 |
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY |  |
(84-028) 37 755 057 | Feedback |
| 19 Nguyen Huu Tho St. Dist.7, HCM |  |
thuvien@tdtu.edu.vn | ||